|
Anxiety Disorders
|
0.510 |
Biomarker
|
group |
BEFREE |
These results indicate that GALR2/NPYY1R interactions can provide a novel integrative amygdaloid mechanism in anxiety.
|
24841617 |
2015 |
|
Anxiety Disorders
|
0.510 |
Therapeutic
|
group |
RGD |
Role of neuropeptide Y Y₁ and Y₂ receptors on behavioral despair in a rat model of depression with co-morbid anxiety.
|
21803058 |
2012 |
|
Anxiety Disorders
|
0.510 |
Therapeutic
|
group |
CTD_human |
Neuropeptide Y Y1 receptor-mediated anxiolysis in the dorsocaudal lateral septum: functional antagonism of corticotropin-releasing hormone-induced anxiety.
|
11440811 |
2001 |
|
Obesity
|
0.500 |
Biomarker
|
disease |
CTD_human |
Several genes and transcripts involved in lipolysis were down-regulated, such as AKAP1, PRKAR2B, Gi and CIDEA, whereas NPY1R and CES1 were up-regulated, when comparing obese to lean subjects.
|
20975297 |
2010 |
|
Obesity
|
0.500 |
Biomarker
|
disease |
RGD |
Difference of NPY and its receptor gene expressions between obesity and obesity-resistant rats in response to high-fat diet.
|
17447163 |
2007 |
|
Obesity
|
0.500 |
Biomarker
|
disease |
MGD |
Behavioural, neural and cardiovascular adaptations in mice lacking the NPY Y1 receptor.
|
15652259 |
2005 |
|
Obesity
|
0.500 |
Biomarker
|
disease |
MGD |
Chronic neuropeptide Y infusion into the lateral ventricle induces sustained feeding and obesity in mice lacking either Npy1r or Npy5r expression.
|
14525913 |
2004 |
|
Obesity
|
0.500 |
Biomarker
|
disease |
MGD |
Voluntary alcohol consumption is controlled via the neuropeptide Y Y1 receptor.
|
11826154 |
2002 |
|
Obesity
|
0.500 |
Biomarker
|
disease |
MGD |
Increased insulin concentrations and glucose storage in neuropeptide Y Y1 receptor-deficient mice.
|
11287097 |
2001 |
|
Schizophrenia
|
0.320 |
Biomarker
|
disease |
BEFREE |
In this study, we measured the mRNA expression levels of dysbindin-1, NRG-1 and two other genes (NPY1R and GNAO1) in immortalized lymphocytes from 45 patients with schizophrenia and 45 controls using real-time quantitative reverse transcriptase-PCR.
|
21512575 |
2011 |
|
Schizophrenia
|
0.320 |
Biomarker
|
disease |
PSYGENET |
In this study, we measured the mRNA expression levels of dysbindin-1, NRG-1 and two other genes (NPY1R and GNAO1) in immortalized lymphocytes from 45 patients with schizophrenia and 45 controls using real-time quantitative reverse transcriptase-PCR.
|
21512575 |
2011 |
|
Schizophrenia
|
0.320 |
Biomarker
|
disease |
PSYGENET |
The expression of the neuropeptide Y receptor Y1 gene (NPY1R localized at 4q31.3-q32) and the human guanine nucleotide-binding regulatory protein Go-alpha (GNAO1 localized at 16q13) was significantly decreased in individuals with schizophrenia compared to unaffected family controls by microarray and real-time PCR.
|
14741323 |
2004 |
|
Schizophrenia
|
0.320 |
Biomarker
|
disease |
BEFREE |
The expression of the neuropeptide Y receptor Y1 gene (NPY1R localized at 4q31.3-q32) and the human guanine nucleotide-binding regulatory protein Go-alpha (GNAO1 localized at 16q13) was significantly decreased in individuals with schizophrenia compared to unaffected family controls by microarray and real-time PCR.
|
14741323 |
2004 |
|
Psychotic Disorders
|
0.310 |
Biomarker
|
group |
PSYGENET |
It is possible that genetic variants of the NPY1R gene affect the NPY-NPY receptor type Y1 signaling system in the brain, which may result in susceptibility to methamphetamine dependence or the development of methamphetamine psychosis, but the present findings need to be confirmed on replication.
|
19566775 |
2009 |
|
Psychotic Disorders
|
0.310 |
GeneticVariation
|
group |
BEFREE |
Genotypic distribution of the NPY1R gene showed a significant association with methamphetamine dependence and psychosis (P = 0.04), whereas the NPY gene had no significant association with them.
|
19566775 |
2009 |
|
Nonorganic psychosis
|
0.310 |
GeneticVariation
|
disease |
BEFREE |
Genotypic distribution of the NPY1R gene showed a significant association with methamphetamine dependence and psychosis (P = 0.04), whereas the NPY gene had no significant association with them.
|
19566775 |
2009 |
|
Nonorganic psychosis
|
0.310 |
Biomarker
|
disease |
PSYGENET |
It is possible that genetic variants of the NPY1R gene affect the NPY-NPY receptor type Y1 signaling system in the brain, which may result in susceptibility to methamphetamine dependence or the development of methamphetamine psychosis, but the present findings need to be confirmed on replication.
|
19566775 |
2009 |
|
Psychoses, Drug
|
0.300 |
Biomarker
|
disease |
CTD_human |
Association between neuropeptide Y gene and its receptor Y1 gene and methamphetamine dependence.
|
19566775 |
2009 |
|
Psychoses, Substance-Induced
|
0.300 |
Biomarker
|
disease |
CTD_human |
Association between neuropeptide Y gene and its receptor Y1 gene and methamphetamine dependence.
|
19566775 |
2009 |
|
Amphetamine-Related Disorders
|
0.300 |
Biomarker
|
group |
CTD_human |
Association between neuropeptide Y gene and its receptor Y1 gene and methamphetamine dependence.
|
19566775 |
2009 |
|
Amphetamine Addiction
|
0.300 |
Biomarker
|
disease |
CTD_human |
Association between neuropeptide Y gene and its receptor Y1 gene and methamphetamine dependence.
|
19566775 |
2009 |
|
Amphetamine Abuse
|
0.300 |
Biomarker
|
disease |
CTD_human |
Association between neuropeptide Y gene and its receptor Y1 gene and methamphetamine dependence.
|
19566775 |
2009 |
|
Toothache
|
0.300 |
Therapeutic
|
phenotype |
CTD_human |
Neuropeptide Y Y1 receptor effects on pulpal nociceptors.
|
18809749 |
2008 |
|
Diastematomyelia
|
0.300 |
Biomarker
|
disease |
CTD_human |
Gastrointestinal hormones (anorexigenic peptide YY and orexigenic ghrelin) influence neural tube development.
|
17400914 |
2007 |
|
Neural Tube Defects
|
0.300 |
Biomarker
|
group |
CTD_human |
Gastrointestinal hormones (anorexigenic peptide YY and orexigenic ghrelin) influence neural tube development.
|
17400914 |
2007 |